EUVIMEDOpdag EUVIMED
Crossref

Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study

Shan-Shan Qi, Zhi Chen, Yu Du, Ming Sun, Zhuo Wang, Fei Long, Linlin Luo, Hao Xiong iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30659 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2023. Written by Shan-Shan Qi and 7 co-authors. Institution: Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Major MEDLINE topics: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Hematologic Neoplasms. Cited 6 times so far (Crossref); 27 references. Funded by: Natural Science Foundation of Hubei Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Post‐transplant cyclophosphamide (PTCy) has been recommended for prevention of graft‐versus‐host disease (GvHD) following haploidentical hematopoietic cell transplantation (haplo‐HCT) for treatment of malignant blood diseases, but disease relapse remains a problem. Although donor lymphocyte infusion (DLI) is reported to be effective for treating post‐transplantation relapse, the efficacy and safety of prophylactic‐DLI (pro‐DLI) post haplo‐HCT, and PTCy in pediatric patients with hematological malignancies is unknown.

Methods

We retrospectively analyzed the outcomes of 54 pediatric patients with high‐risk myeloid neoplasms who received a PTCy regimen for GvHD prophylaxis and pro‐DLI after haploidentical peripheral blood stem cell transplantation. The high‐risk myeloid neoplasms in this cohort included acute myeloid leukemia ( n = 46) and myelodysplastic syndromes ( n = 8).

Results

Median follow‐up was for 19.7 (range: 3.4–46.6) months. The cumulative incidences of grade II–IV and III–IV acute GvHD were 37.0% (95% CI: 22.7%–48.7%) and 16.7% (95% CI: 6.1%–26.0%), respectively. There were no graft‐failure events, and the 2‐year rate of moderate/severe chronic GvHD was 8.1% (95% CI: 0%–16.7%). The 2‐year non‐relapse mortality, relapse, disease‐free survival, GvHD‐free relapse‐free survival, and overall survival rates were 5.1% (95% CI: 0%–11.7%), 16.6% (95% CI: 5.3%–26.6%), 78.9% (95% CI: 68.0%–91.6%), 62.2% (95% CI: 49.4%–78.3%), and 87.3% (95% CI: 78.3%–97.4%), respectively.

Conclusions

Prophylactic donor lymphocyte infusion in the setting of haploidentical hematopoietic cell transplantation with post‐transplant cyclophosphamide appears to be effective and safe in pediatric patients with high‐risk myeloid neoplasms.

Subjects

MeSH terms (MEDLINE)

Hematopoietic Stem Cell TransplantationGraft vs Host DiseaseHematologic NeoplasmsHumansChildRetrospective StudiesCyclophosphamideRecurrenceLymphocytes

Author keywords

donor lymphocyte infusionhematopoietic stem cell transplantationmyeloid neoplasmspediatric patientspost-transplant cyclophosphamide

Substances

Cyclophosphamide

Authors and institutions

  • Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID profiles: Hao Xiong

Funding

  • Natural Science Foundation of Hubei Province

Cite

APA

Qi, S. S., Chen, Z., Du, Y., Sun, M., Wang, Z., Long, F., Luo, L., & Xiong, H. (2023). Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30659

Vancouver

Qi SS, Chen Z, Du Y, Sun M, Wang Z, Long F, et al. Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30659

BibTeX
@article{Qi2023,
  author = {Qi, Shan-Shan and Chen, Zhi and Du, Yu and Sun, Ming and Wang, Zhuo and Long, Fei and Luo, Linlin and Xiong, Hao},
  title = {Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post‐transplant cyclophosphamide for treatment of high‐risk myeloid neoplasms in children: A retrospective study},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30659}
}
Start for free →